
Daniel Canter, MD, shares his thoughts on the potential impact of 89Zr-girentuximab for kidney cancer management, if approved.

Dr. Daniel Canter is a fellowship-trained urologic oncologist specializing in the care of patients with urologic cancers, including advanced prostate cancer. He leads Georgia Urology’s Advanced Prostate Cancer team and clinical research efforts, providing expert, longitudinal care.
Dr. Canter completed his urology residency at the University of Pennsylvania and fellowship training at Fox Chase Cancer Center. He has authored over 125 peer-reviewed publications and numerous textbook chapters and is an active member of several professional organizations in urologic oncology.
Outside of work, Dr. Canter enjoys spending time with his wife, two children, and their dog.
Dr. Canter’s Georgia Urology Page - https://www.gaurology.com/our-physicians/physician/daniel-canter-m-d/
Georgia Urology's Homepage - https://www.gaurology.com